Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

Summary

This study was conducted because the FDA requested clinical information on potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium from a 1-year (minimum) post-approval clinical study to support that there are no adverse effects on the corneal endothelium following intravitreal injections of Macugen.

Timeline

Start

2010-04-22

Primary completion

2019-11-14

Completion

2019-11-14

Drugs

Indications